162 chapter 2 Table 28. Estimated pooled test performance of the miRInform® thyroid test in indeterminate thyroid nodules ni test + test - test ? nH (%) TP FP FN TN malignant (TP+FN/ni) sensitivity (95% CI), % specificity (95% CI), % LR+ (95% CI) LR- (95% CI) Nikiforov 2011* 461 63 398 0 461 (100%) 55 8 38 360 20% 59 (48-69) 98 (96-99) 27.20 (13.43-55.11) 0.42 (0.33-0.53) Ohori 2013* 424 64 320 40 384 (100%) 60 4 54 266 27% 53 (43-62) 99 (96-100) 35.53 (13.23-95.43) 0.48 (0.40-0.58) Beaudenon-Huibregtse 2014* 80 14 66 0 41 (51%) 8 3 9 21 21% 47 (23-72) 88 (68-97) 3.76 (1.17-12.16) 0.61 (0.38-0.97) Labourier 2015* 109 34 75 0 109 (100%) 24 10 11 64 32% 69 (51-83) 86 (77-93) 5.07 (2.73-9.42) 0.36 (0.22-0.60) Valderrabano 2016* 105 15 83 7 56 (57%) 10 3 9 34 18% 53 (29-76) 92 (78-98) 6.49 (2.02-20.82) 0.52 (0.32-0.84) POOLED RESULTS 1,179 190 942 47 1,051 (92.8%) 157 28 121 745 23.6% 58.1 (50.7-65.2) 95.2 (89.2-98.0) 12.21 (5.38-27.75) 0.44 (0.37-0.52) *: study applied miRInform® test. FN: false negative. FP: false positive. LR+: positive likelihood ratio. LR-: negative likelihood ratio. nH: number of indeterminate thyroid nodules with conclusive index test and histopathological follow-up. ni: number of indeterminate thyroid nodules. test+: number of positive index tests. test-: number of negative index tests. test?: number of unknown or nondiagnostic index tests. TN: true negative. TP: true positive.
RkJQdWJsaXNoZXIy MTk4NDMw